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RESUME 
Introduction: 
Etudier: 1) l'efficacité à long terme des injections intravitréennes (IVT) de 
ranibizumab dans le traitement de la membrane néovasculaire (MNV) du myope fort,                    
2) le rôle de l'imagerie multi-modale (tomographie en cohérence optique et 
angiographie fluorescéinique) et du changement d’acuité visuelle dans la décision de 
traitement avant chaque injection.  
Matériel et méthodes:  
Cette étude monocentrique, rétrospective, non-randomisée, a été réalisée à l’Hôpital 
Ophtalmique Jules Gonin de Lausanne. Elle a inclu les patients traités par IVT 
de ranibizumab pour MNV myopique suivis ≥24 mois. Après une dose de charge de 
1 à 3 injections, le suivi se basait sur un traitement à la demande (pro re nata). 
L’examen ophtalmologique, la mesure de la meilleure acuité visuelle corrigée 
(MAVC), et la tomographie en cohérence optique (OCT) ont été réalisés à chaque 
visite, et l'angiographie fluorescéinique (AF) a été faite initialement et en cas de 
suspicion d’activité néovasculaire. Les critères de retraitement incluaient les 
métamorphopsies, la perte d’acuité visuelle de ≥5 lettres ETDRS, les signes 
d’exsudation à l’OCT et/ou à l’AF. 
Résultats: 
24 yeux de 24 patients ont été inclus avec un suivi moyen de 49 mois (25-84 mois). 
La MAVC moyenne a augmenté de initialement 62.8 ±13.8 lettres à 72.8 ±12.9 
lettres à la dernière visite (p=0.001). Le nombre moyen d’injections était 2.2 la 
première année, et inférieur à 1 les années suivantes. Les sensibilités de l’AF, de 
l’OCT spectral domain, et de la perte de MAVC ≥5 lettres étaient respectivement  
62.6%, 51.4%, and 40%. L’angiographie fluorescéinique montrait une sensibilité 
supérieure à l’OCT dans la décision de traitement (p=0.007). 
Conclusions:  
Les IVT de ranibizumab ont démontré une efficacité fonctionnelle à long terme avec 
un nombre réduit d’injections pour la MNV myopique. L’angiographie fluorescéinique 
a un rôle prépondérant dans la décision de traitement des MNV actives.  
 
 
MOTS CLES  
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ABSTRACT 
Background:  
To report our functional results of efficacy of intravitreal ranibizumab (IVR) for submacular 
choroidal neovessels (CNV) in high myopia, and to compare the role of optical coherence 
tomography (OCT), fluorescein angiography (FA) and visual acuity changes in the treatment 
decision prior to each injection. 
Patients and methods:  
This is a retrospective study performed in Jules Gonin Eye Hospital. It included all patients 
with myopic CNV treated with IVR injections with a minimal follow-up of 24 months. After an 
induction dosing from 1 to 3 injections, the follow-up was based on a PRN regimen. 
Ophthalmic evaluation, best corrected visual acuity (BCVA), and OCT were done at each 
visit, and FA at baseline and if neovascular activity was suspected. Retreatment criteria 
included metamorphopsia, visual loss of ≥5 ETDRS letters, any fluid on OCT and/or leakage 
on FA. 
Results:  
24 eyes were included in the study. Mean follow-up was 49 months. Mean BCVA improved 
significantly from 62.8 ±13.8 letters at baseline to 72.8 ±12.9 letters at last follow-up visit 
(p=0.001). The mean number of injections was 2.2 in the first year and below 1 for the 
following years. The sensitivity of FA, SD OCT, and BCVA loss ≥ 5 letters were 62.6%, 
51.4%, and 40% respectively. The FA showed significant higher sensitivity in treatment 
decision than OCT (p=0.007). 
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Conclusion: 
Our study showed that IVR provides a significant long term visual benefit in myopic CNV with 
a small number of injections. FA has a preponderant role in the treatment decision of active 
myopic CNV.  
PRECIS 
Our study showed long term efficacy of ranibizumab in the treatment of myopic CNV. We 
studied also the contribution of different modalities (OCT, FA and BCVA loss) in the 
retreatment decision. 
 
ABSTRAKT 
Hintergrund: 
Ziel der Studie war es, die funktionellen Resultate von intravitrealem Ranibizumab (IVR) für 
submakuläre choroidale Neovaskularisationen (CNV) bei hoher Myopie zu beschreiben, und 
dabei die Rolle der optischen Kohärenztomographie (OCT), der Fluoreszein Angiographie 
(FA) und von Visus Veränderungen in Bezug auf die Behandlungsentscheidung zu 
untersuchen. 
Patienten und Methoden: 
Diese retrospektive Studie schloss Patienten ein, die im Universitätsspital Jules Gonin 
wegen myoper CNV mit IVR behandelt wurden und mindestens 24 Monate kontrolliert 
respektive behandelt wurden. Nach initialen 1-3 monatlichen IVR Dosen, wurden die 
Patienten gemäss einem pro re nata (PRN) Schema weiterbehandelt. Bei jeder 
Untersuchung wurde ein kompletter ophthalmologischer Status erhoben, die best korrigierte 
Sehschärfe (BCVA) gemessen, und ein OCT gemacht. Eine FA wurde zu Beginn 
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durchgeführt und bei Verdacht auf neovaskuläre Aktivität. Wiederbehandlungskriterien 
beinhalteten Metamorphopsien, einen Visusverlust von 5 oder mehr ETDRS Buchstaben, 
und/oder im OCT nachgewiesene Flüssigkeit, respektive exudative Aktivität in der FA. 
Resultate: 
Vierundzwanzig Augen mit mittlerer Nachbeobachtungszeit von 49 Monaten wurden in die 
Studie eingeschlossen. Die Sehschärfe verbesserte sich im Mittel signifikant von initial 62.8 
±13.8 Buchstaben auf 72.8 ±12.9 Buchstaben bei der letzten Untersuchung (p=0.001). Die 
mittlere Anzahl IVR lag bei 2.2 im ersten Jahr und unter 1 in den Folgejahren. Die Sensitivität 
der FA, des OCT, und des BCVA Verlustes von 5 oder mehr Buchstaben lag bei 62.6%, 
51.4%, respektive 40%. Die FA zeigte signifikant höhere Sensitivität bei der 
Wiederbehandlungsentscheidung als das OCT (p=0.007). 
Schlussfolgerung: 
Diese Studie zeigte langfristige und signifikante Visuserfolge der IVR Behandlung für myope 
CNV mit sehr geringer Anzahl von Injektionen. Die FA hat eine zentrale Rolle in der 
Wiederbehandlungsentscheidung bei aktiven myopen Membranen. 
 
PRECIS 
Diese Studie evaluiert die Langzeitresultate der Ranibizumab Behandlung für myope 
subretinal Membranen. Zudem wurde die Sensitivität von diversen Untersuchungsmodalitätet 
hinsichtlich der Wiederbehandlungsentscheidung evaluiert. 
 
KEY WORDS 
Ranibizumab, myopic neovascularization, anti-VEGF  
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INTRODUCTION 
 
High or pathologic myopia (≥-6 diopters) is a major cause of visual impairment  worldwide [1]. 
Choroidal neovascularization (CNV) occurs in 5 to 10% of the cases [2, 3]. In young patients, 
high myopia is the first cause of CNV[4]. Various studies showed that the natural history of 
this complication is unfortunately often poor [5, 6].  
Since the 2000’s, photodynamic therapy (PDT) was used to treat neovascularization with 
moderate benefits. The results at one year were very promising, but  the results at 2 years [7] 
and more [1, 8] didn’t report superiority compared to placebo. 
Since 2006, intravitreal anti-vascular endothelial growth factor (anti-VEGF) drug gradually 
replaced PDT, and became since 2009 the first treatment in clinical practice [9, 10].  
Many studies demonstrated a significant short term efficacy of anti-VEGF, with a mean visual 
acuity improving at 6 [11] and 12 months [12, 13]. 
Recently, two high-evidence phase II and III studies (respectively  REPAIR  [14] and 
RADIANCE [15] studies) have confirmed the very good prognosis at 12 months of patients 
treated by intravitreal ranibizumab (Novartis Pharma AG, Basel, Switzerland Lucentis®). 
Fewer  studies with a longer follow-up from 24 to 48 months also showed  a functional 
benefit over time [16–20].  
 
The purposes of this study were: 1/ to report our long term functional results of efficacy of 
intravitreal ranibizumab for submacular neovessels in high myopia and 2/ to compare the role 
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of spectral domain optical coherence tomography (OCT), fluorescein angiography (FA) and 
visual acuity changes in the treatment decision prior to each injection. 
 
METHODS 
 
This is a monocentric retrospective nonrandomized study performed in the Jules Gonin 
University Eye Hospital of Lausanne including high myopic patients treated with intravitreal 
ranibizumab injections for submacular CNV with a minimal follow-up of 24 months after the 
first injection, from 2006 to 2013. Our study respects the tenets of Declaration of Helsinki and 
at the time of the first injection all patients gave an informed written consent regarding the 
off-label use of ranibizumab.  
The database of the Medical Retina unit, the off-label ranibizumab invoicing and the 
operating room register were used for patient’s identification. All folders were then reviewed 
by a retina specialist (AA) to confirm that the inclusion criteria were met. 
Inclusion criteria were: 1/ presence of active sub- or juxta-foveolar subretinal neovessels 
secondary to high myopia defined as a minimal refractive error of 6 diopters (D), 2/ baseline 
BCVA ranging from 5 to 80 ETDRS letters, 3/ treatment with ranibizumab intravitreal 
injection, 4/ minimal follow-up of 24 months after the first injection defined as baseline. 
 Exclusion criteria were: 1/ PDT or laser treatment during the last 6 months before the first 
injection, 2/ prior intravitreal bevacizumab (Avastin®) injection, 3/ presence of foveolar 
atrophy on autofluorescence, 4/ presence of other ocular pathology that could interfere with 
the visual outcome during the study (epiretinal membrane, myopic foveoschisis, age related 
macular degeneration, and other diseases). 
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The initial examination included : BCVA measurement with Early Treatment Diabetic 
Retinopathy Study (ETDRS) charts, dilated fundus examination, autofluorescence, colour 
fundus photography, quantitative and qualitative macular measurement by time domain- or 
spectral domain-optical coherence tomography (TD-OCT Stratus OCT, Zeiss Inc; SD-OCT, 
Cirrus, Carl Zeiss Meditec, Inc., Oberkochen, Germany and Spectralis Heidelberg®, 
Heidelberg, Germany), and fluorescein angiography (FA) (TopCon TRC-50IX (Tokyo, 
Japan), Heidelberg HRA®, Heidelberg, Germany). Because OCT machines changed from 
time domain (TD) to spectral domain (SD) OCT, quantitative anatomical outcome could not 
be reported in our study.  
BCVA measurement, fundus examination and OCT were performed at each visit and FA was 
performed only if needed. 
Criteria to define an active neovascularisation were: 1/ recent vision loss of ≥ 5 letters and/ or 
recent metamorphopsia, 2/ new subretinal haemorrhage at funduscopy examination (in 
presence of a confirmed neovascular subretinal network on OCT and/or FA), 3/ intra- or 
subretinal fluid on OCT, and 4/ leaking neovascular network on FA.  
The treatment regimen was dependent on the ophthalmologist in charge of the patient. After 
an induction dose of 1 to 3 injections, the follow-up regimen was based on a pro re nata 
(PRN) regimen: in case of recurrence (presence of one criteria of active neovascularisation 
at least) a single injection was performed with an examination one month later. 
Injections were stopped when BCVA was stable over two consecutive follow-up 
examinations in absence of any exudative sign on fundus, OCT and FA (if performed). 
 
To define the comparative contribution of any fluid on OCT, presence of CNV on FA, and 
BCVA change compared to the last visit in the treatment decision, we considered the set of 
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these 3 arguments along with the presence of subjective symptoms (metamorphopsia) as 
reference for all treatment decisions in real life setting. Thirty seven treatment decisions were 
analysed over the time of our study. 
For this analysis, we included only the patients examined with SD-OCT from baseline (SD-
OCT Cirrus or Spectralis Heidelberg). FA on Topcon Corp and Heidelberg HRA were pooled 
and analysed together whereas SD-OCT Cirrus and Spectralis were processed separately. 
FA and OCT were analysed separately by two different retina specialists (AA, AD) and 
another investigator (ML) reviewed BCVA change before each treatment decision.  
The maximal duration between OCT and FA exams and treatment decision was 2 weeks.  
Statistical analysis was performed using SPSS for Windows software (version 19.0, SPSS, 
Inc.). Descriptive analyses are reported as means standard deviation for continuous variable 
and as percentage for qualitative variables. BCVA at baseline, and different follow-up 
evaluations were compared using Wilcoxon test. The sensitivities of different modalities were 
reported as percentage, and compared using Fisher exact test. A 2-tailed probability of 0.05 
or less was considered statistically significant.  
 
RESULTS 
 
Baseline characteristics 
Twenty four eyes (24 patients) were included in this study. The mean patients’ age was 57 
years (range: 40-82). Male to female ratio was 0.55. The mean follow-up was 49 months 
(range: 25-84 months). Forty six percent of eyes were pseudophakic. The mean spherical 
equivalent at diagnosis was -16 diopters (range: -27 to -6 D). Three out of 24 included eyes 
(13%) were previously treated with PDT at least 6 months prior to baseline. All patients 
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showed an underlying lacquer cracks on FA at the time of diagnosis of active myopic CNV.  
The CNV was classic in 100% of cases, retrofoveal in 22 (92%) eyes and juxtafoveal in 2 
eyes.  
 
Visual outcomes 
 
At baseline, the mean BCVA was 62.8 ±13.8 ETDRS letters. BCVA improved significantly to 
71.7 ±14.7 ETDRS letters at 1 year (p= 0.001; n=24), 73.2 ± 10.7 ETDRS letters at 2 years 
(p= 0.001; n=24), 69.1± 11.7 ETDRS letters at 3 years (p= 0.005; n=15), and 68.7±12.3 
ETDRS letters at 4 years (p= 0.012; n= 14). The mean BCVA at last follow up visit was 72.8 
±12.9 ETDRS letters (p=0.001). The BCVA changes over time are illustrated in Figure 1.  
Figure 2 illustrates the proportion of eyes who gained >5, >10, and >15 ETDRS letters at 
month 12, 24, 36, and 48 months. 20.8% and 41.7% of patients gained respectively ≥15 
letters or ≥10 letters at 12 months (N=24). These results was maintained at 48 months follow 
up (n=14). 
Number of injections 
The mean number of injections during the first, second, third, and fourth year were 
respectively: 2.2, 0.4, 0.1 and 0.4 injections. Figure 3 shows the number of injections at 
month 24. 
Anatomical outcome 
At the last visit, 100% of the eyes showed absence of leakage and fluid on FA and OCT. 
21% of eyes developed macular atrophy on autofluorescence when comparing baseline and 
last exams, 47% of eyes developed fibrosis on SD OCT.  
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Eyes with atrophy had longer follow-up (FU) period (mean 64.4 months) compared to eyes 
without atrophy (mean FU period 45 months; p=0.04). The mean number of injections was 
respectively 6.6 injections in eyes with atrophy and 2.8 in eyes without atrophy (p=0.13) 
There was no difference in the follow up period (mean FU= 51.9 months in eyes with fibrosis 
and mean FU= 47 in eyes without fibrosis; p=0.66) and in the number of injections (mean 
number of injections was 4.3 in eyes with fibrosis and 2.5 in eyes without fibrosis; p=0.97) 
between eyes which developed fibrosis or not. 
Treatment decision 
When compared to the gold standard for treatment decision which consisted of the 
combination of: presence of BCVA loss of ≥5 ETDRS letters, presence of any fluid on OCT 
and/or evidence of leakage on FA, the sensitivity of the different modalities was: 62.6% for 
FA, 53.8% for OCT performed with Cirrus, 45.5% for OCT performed with Heidelberg (the 
difference was not significant between the two OCT types; p=0.728), and 40% for objective 
vision loss of ≥5 ETDRS letters. This is illustrated in the figure 4. There was a significant 
difference in sensitivity between OCT and FA (p=0.007) (Figure 5).  
Sensitivity of combined methods was 70.2% for OCT and/or FA, 73% for FA and/or vision 
loss of ≥5 ETDRS letters, and 60% for OCT and/or vision loss. There was concomitant 
positive findings on OCT and FA only in 43.3% of treatment decisions.  
 
 
 
DISCUSSION 
 
Various studies showed the efficacy of intravitreal anti-VEGF agent for treatment of myopic 
CNV in both short and long term follow up [11–21]. 
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Our results correlate well with previously published long term studies. Indeed, we found that 
intravitreal ranibizumab injection provides a significant visual improvement sustained up to 4 
years. The mean BCVA changes from 63 ETDRS letters at baseline, to 72 ETDRS letters at 
month 12, 73 ETDRS letters at month 24, and 69 ETDRS letters at months 36 and 48. In 
comparison, Franqueira et al.[16], in a retrospective study of 40 eyes using ranibizumab only, 
reported a mean visual improvement from 55.4 letters at baseline to 59.7 letters at month 12, 
61.8 letters at month 24, and 63.4 letters at month 36. Hefner et al. [22] retrospectively 
studied 15 eyes treated with ranibizumab , and reported an improvement of mean BCVA 
from 50 letters at baseline to 70 letters at months 12, 24 and 36. A retrospective analysis of 
Ruiz Moreno et al. [23] studied 92 eyes treated by either bevacizumab or ranibizumab, and 
reported a mean BCVA change from 46.1 letters at baseline to 53.1 at month 48. They did 
not find a significant difference in efficacy between these two anti-VEGFs agents. Several 
other studies already showed no significant difference in term of vision improvement between 
bevacizumab and ranibizumab [11,17, 23]. In our study, the mean baseline BVCA was higher 
than in all previously mentioned studies. This could explain our relative small percentage of 
patient gaining ≥15 letters or more as compared with RADIANCE study [15]. Over time, a 
gradual loss in BCVA is observed in our cohort, and that could be related to degenerative 
retinal changes over time and/or to loss of follow-up of patients with good functional 
outcome.  
The number of injections given during the follow-up of our patients was low with a mean of 
2.2 injections in the first year and less than one injection thereafter. These results are 
consistent with other studies (such as REPAIR and RADIANCE studies) where the mean 
number of injections during the first year was respectively 1.9 injections (REPAIR), 4 
injections (RADIANCE subgroup that received 2 IVR as loading dose) and 2 injections 
(RADIANCE subgroup that received one IVR as loading dose) [14, 15]. In addition, 83% of 
patients received a maximum of 3 injections at 24 months compatible with a significant 
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functional benefit. These findings obviously contrast with results reported in exudative 
macular degeneration treated with repeated anti-VEGF injection. Indeed, the chronic 
degenerative changes underlying wet age-related macular degeneration are not present as 
such in myopic neovascularisation. This rapid initial benefit was also found in REPAIR and 
RADIANCE studies [14, 15]. These results are encouraging for patient counselling when 
started on anti-VEGF therapy. The small number of injections per year seems to valuate a 
PRN treatment regimen starting from baseline in clinical practice.  
Twenty one percent of our patients developed macular atrophy on autofluorescence during 
the follow-up. Patients with atrophy had an overall longer follow-up and higher number of 
injections when compared to the whole cohort. Peiretti et al [20] reported 33% of atrophy 
after 4 years. Yoshida et al. [24] reported that in the natural course of high myopic patients 
96.3% developed atrophy on colour fundus photographs or FA after 10 years. Besides the 
natural evolution, the higher number of injections may contribute to atrophy progression. In 
the CATT study [25], patients on monthly treatment showed higher progression of 
geographic atrophy over time. Even if the physiopathology of exudative age-related macular 
degeneration and myopic neovascularisation is different, accumulation of anti-VEGF drug in 
the retinal pigmentar epithelium [26]  can have toxic effect in both conditions.  
Peiretti et al. reported fibrosis in 71% of treated eyes at 4 year. 47% of our patients 
developed fibrosis at the last visit. In both series, fibrosis overcomes the development of 
geographic atrophy. This finding is in accordance to the type 2 CNV mostly found in CNV 
patients [27]. In our cohort, all patients had a classic CNV. Our results showed that fibrosis 
was not related to time of follow-up, what is confirmed in the retrospective study of Lai et al. 
[17] who analysed visual outcome of 37 treatment-naïve eyes treated by ranibizumab or 
bevacizumab and reported 56.8% of fibrosis at 3 months. This suggests a potential role for 
combined anti-PDGF [28, 29] and anti-VEGF as baseline treatment of myopic CNV. 
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Multimodal imaging is today the gold standard to confirm the diagnosis of active CNV in 
pathological myopia. Our analysis showed the higher sensitivity of FA for treatment decision 
(62%). Leveziel et al [30] also reported a high sensitivity of FA (82%). His study investigated 
the role of imaging only at baseline visit for active CNV which may explain the difference 
between these two results.  SD-OCT and FA signs of activity might be more obvious at 
baseline than during the follow-up.  
OCT analysis found no significant difference between Cirrus and Heidelberg SD-OCT 
sensitivities. Sensitivity was 53.8% for Cirrus OCT and 45.5% for Heidelberg OCT. Cirrus 
OCT was mostly performed at the beginning of the study, then Spectralis SD-OCT 
progressively replaced in our clinical practice by. Leveziel et al. [30] reported a sensitivity of 
48.6% for Heidelberg SD-OCT in the diagnosis of new myopic CNV on OCT. Both studies 
showed a superiority of fluorescein angiography over OCT in the treatment decision of 
myopic CNV. Sensitivity of combined methods was the highest (73%) for FA and/or vision 
loss and was only of 60% for OCT and/or vision loss. This last combination may reflect the 
overall routine clinical practice in most places. Concomitant positive findings on OCT and FA 
were met in only 43.3% of treatment decisions. Leveziel et al. mentioned an even lower 
agreement between FA and OCT of 16.1%. This illustrates well that FA cannot simply be 
replaced by SD-OCT in clinical practice and that FA still play a major role in the management 
of myopic CNV. 
Our study has limitations including a relatively small number of eyes and the monocentric 
retrospective design. The absence of control group for analysis of treatment decision 
specificity was also a limitation. 
In conclusion, our 4-year results analysis of patients with high myopic CNV treated by 
intravitreal ranibizumab injection on a PRN regimen confirmed an excellent long term visual 
prognosis with a low number of injections. Long term anatomical evolution showed subfoveal 
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fibrosis in half of our patients suggesting a role for combined anti VEGF-anti fibrotic drug. 
The role of fluorescein angiography remains preponderant in the treatment decision of CNV 
due to high myopia. 
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FIGURES 
 
 
 
 
Figure 1. Mean visual acuity change over time 
This graph shows the mean visual acuity change over time. Mean VA gain was 9±15, 10±9, 
6±9, 6±9 letters at 1, 2, 3, 4 years respectively. The mean visual improvement at last visit 
was significant (p=0.001).  
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Figure 2. Vision gain at 12, 24, 36 and 48 months 
This figure represents the percentage of eyes gaining >5, >10, and > 15 ETDRS letters at 
12, 24, 36, and 48 months. 
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Figure 3. Number of injections at month 24 
This figure shows the number of patients (N) who necessitated 1, 2-3, 4-6, and more than 7 
injections at month 24. 83% of patients received a maximum of 3 injections at month 24. 
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Figure 4. Sensitivity of FA, OCT and vision loss of ≥5 ETDRS letters for decision of 
treatment. 
Fluorescein angiography was the most sensitive modality in the treatment decision. The 
difference in sensitivity between OCT and FA was significant (p=0.007).  
 
 
a.         b.  
 
Figure 5. FA and SD-OCT at the time of baseline treatment decision in patient 24 
a. early phase of fluorescein angiography (Topcon) showing a clear active subfoveal CNV, b. 
Cirrus SD-OCT (Zeiss) showing a subretinal hyperreflectivity without evident fluid. 
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